EAU 2021 | Improving anti-PD-1/PD-L1 therapy for localized bladder cancer

Christiaan De Jong, MD, Erasmus University Medical Center, Rotterdam, The Netherlands, talks on the need for improvement of anti-PD-1/PD-L1 therapy for patients with localized bladder cancer, commenting on low response rates in these patients. Dr De Jong suggests that combinatorial approaches, such as with BCG or alternative immune checkpoint inhibitors, may improve response rates. In particular, Dr De Jong comments on the potential benefits of combining chemotherapy with anti-PD-1/PD-L1 therapies, or combining PARP inhibitors with anti-PD-1/PD-L1 drugs to increase the mutational burden of tumors and trigger an improved immune response. This interview took place at the virtual European Association of Urology (EAU) Virtual Meeting 2021.